Clinical trials: Enoxaparin
Acute Respiratory Failure, SARS CoV 2 Infection
Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients
Coronavirus Disease (COVID-19) is characterized by a hypercoagulable state, sometimes difficult to be managed with heparin. Bivalirudin, a member of the direct thrombin inhibitor drug class, offers potential advantages compared…
- Conditions
- Acute Respiratory Failure, SARS CoV 2 Infection, Anticoagulants
- Trial name
- NCT05334654
- Testing
- Enoxaparin Sodium, Bivalirudin
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University Magna Graecia
Arthroplasty, Replacement, Knee, Thromboembolism
RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery
A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the ef ficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule s [150 or 220 mg once daily…
- Trial name
- NCT00168805
- Testing
- enoxaparin, dabigatran etexilate
- Where
- 105 sites in Australia, Austria and 13 more
- Volunteers
- 2,101 people
- Sponsor
- Boehringer Ingelheim
Prevention, Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg Bay 59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
- Trial name
- RECORD 3 (NCT00361894)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 143 sites in Austria, Belgium and 17 more
- Volunteers
- 2,531 people
- Sponsor
- Bayer
Lower Extremity Deep Venous Thrombosis
Comparison of Subcutaneous Heparin and Enoxaparin for Deep Venous Thrombosis (DVT) Prophylaxis in Surgical Intensive Care Patients
Study hypothesis: Subcutaneous enoxaparin is more effective than subcutaneous heparin in preventing the development of DVT in the general surgical intensive care unit population.
- Trial name
- NCT01325779
- Testing
- heparin, enoxaparin
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Lisa Louwers
Cancer-associated Thrombosis, Thrombocytopenia
STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
Patients with cancer are prone to have blood clots, which are usually treated with blood thinners. The main complication of blood thinners is bleeding.
- Trial name
- NCT05255003
- Testing
- Enoxaparin, Dalteparin, Tinzaparin
- Where
- 4 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Tzu-Fei Wang
Venous Thromboembolism, Cancer
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
The purpose of this study is to show feasibility (efficacy and safety) of Rivaroxaban in the treatment of VTE in cancer patients in comparison to the standard treatment with low molecular weight heparin (LMWH).
- Trial name
- NCT02583191
- Testing
- Rivaroxaban, low-molecular heparine
- Where
- Germany
- Volunteers
- 246 people
- Sponsor
- AIO-Studien-gGmbH
Healthy Volunteers
Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects
In this study, the investigators will evaluate the safety, pharmacokinetics and effect on target biomarkers of coagulation, cell adhesion, and leukocyte and platelet activation of GMI-1271, an E-selectin antagonist, in healthy…
- Trial name
- NCT02271113
- Testing
- GMI-1271, Enoxaparin Sodium (Lovenox®)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlycoMimetics Incorporated
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
The primary objective was to compare the efficacy of once daily [q.d] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-HIP2 (NCT00721760)
- Testing
- Enoxaparin sodium, Semuloparin sodium
- Where
- 25 sites in United States, Argentina and 23 more
- Volunteers
- 1,003 people
- Sponsor
- Sanofi
Venous Thromboembolism (VTE)
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these…
- Trial name
- APEX (NCT01583218)
- Testing
- Betrixaban, Enoxaparin
- Where
- 462 sites in United States, Argentina and 32 more
- Volunteers
- 7,513 people
- Sponsor
- Portola Pharmaceuticals
Venous Thromboembolism
Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT
Subcutaneous enoxaparin is currently the gold standard for VTE chemoprophylaxis. However, the efficacy of chemoprophylaxis with subcutaneous enoxaparin is affected by patient-level factors, thus, resulting in VTE events despite…
- Trial name
- NCT04504318
- Testing
- Apixaban 2.5 MG Oral Tablet, Enoxaparin 40Mg/0.4mL Prefilled Syringe
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Stanford University
Acute Coronary Syndrome, Renal Failure
Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome
The objective of the VALIDE study is to validate that a 25% dose reduction of enoxaparine in patients with moderate renal failure (creatinine clearance between 30 and 50 ml/min) and hospitalized for an acute coronary syndrome…
- Trial name
- NCT00412802
- Testing
- dose adaptation of Enoxaparin, normal injection of Enoxaparine
- Where
- 9 sites in France
- Volunteers
- 67 people
- Sponsor
- French Cardiology Society
Covid19
Cri Analog PG1 Effectiveness and Safety in Covid-19
The Clinical trial aim to evaluate the effectiveness and safety of the administration of the intravenous prostaglandin E1 analog in the reduction of mortality and complications of patients with COVID-19 diagnosis.
- Trial name
- PGE1-COVID19 (NCT04536363)
- Testing
- Analogs, Prostaglandin E1, Standard therapeutic protocol
- Sponsor
- Alonso Vera Torres
Thrombotic Disorders
Prevention of Thromboembolic Events in Total Knee Replacement Patients
The purpose of the study is to find out whether MAA868, is able to prevent blood clots following your medical condition (surgery for knee replacement)
- Trial name
- NCT03393481
- Testing
- MAA868, Enoxaparin
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)
Rationale: a number of recent phase III randomized trials have shown a survival benefit of a treatment with subcutaneous low-molecular weight heparin in patients with advanced solid malignancies.
- Trial name
- SYRINGES (NCT00771563)
- Testing
- cisplatin + docetaxel, cisplatin + docetaxel + enoxaparin
- Where
- 2 sites in Belgium
- Volunteers
- 104 people
- Sponsor
- University Hospital, Antwerp
Venous Thromboembolism, Postpartum Period
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE…
- Conditions
- Venous Thromboembolism, Postpartum Period, Aspirin, Low Molecular Weight Heparin
- Trial name
- NCT06494878
- Testing
- Aspirin, Low-molecular-weight heparin
- Where
- 12 sites in Belgium, Canada and 5 more
- Volunteers
- 8,805 people
- Sponsor
- University of Calgary
Inflammation
Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery
The purpose of this study is to determine if intraocular infusion of low-molecular weight heparin (enoxaparin) influences postoperative inflammation following pediatric cataract surgery with intraocular lens (IOL) implantation.
- Trial name
- NCT00986076
- Testing
- Enoxaparin, Balanced Salt Solution
- Where
- India
- Volunteers
- 23 people
- Sponsor
- Iladevi Cataract and IOL Research Center
Recurrent Miscarriage
Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies
Recurrent miscarriage (RM) is traditionally defined as three or more consecutive miscarriages occurring before 20 weeks post-menstruation.
- Trial name
- LMWH-APAN (NCT01608347)
- Testing
- LMWH+Folic acid, Folic Acid
- Volunteers
- 228 people
- Sponsor
- Omar Mamdouh Shaaban
Gastrointestinal Neoplasms, Thromboembolic Event
Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®
Prospective, monocentric, randomized, parallel group, rater-blinded study using two formulations of Enoxaparin sodium (ENOXA® vs LOVENOX®) to compare the thromboembolic events (symptomatic and asymptomatic) in patients undergoing…
- Trial name
- ENOXACARE (NCT02444572)
- Testing
- Enoxaparin 4000 IU
- Where
- Tunisia
- Volunteers
- 168 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Heart Failure, Respiratory Failure
Reduced Anticoagulation Targets in ECLS (RATE)
The objective of the RATE-trial is to study if reduced anticoagulation targets during ECLS diminish bleeding complications without an increase in thromboembolic complications or a negative impact on outcome.
- Conditions
- Heart Failure, Respiratory Failure, Extracorporeal Membrane Oxygenation, Bleeding
- Trial name
- RATE (NCT04536272)
- Testing
- Heparin, LMWH
- Where
- 8 sites in Netherlands
- Volunteers
- 330 people
- Sponsor
- University Medical Center Groningen
Thromboembolism, Knee Replacement
ARIXTRA Local Study For Registration In China.
This is a local registration study in China to compare the safety and efficacy of ARIXTRA to Enoxaparine in patients undergoing elective major hip or knee replacement or a revision of components.
- Conditions
- Thromboembolism, Knee Replacement, Hip Replacement
- Trial name
- NCT00328939
- Testing
- ARIXTRA infusion, Enoxaparine infusion
- Where
- 7 sites in China
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline